NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment

NCT04435769

CompletedN/A

Sponsor: Pfizer

Conditions: Atrial Fibrillation

Countries: Czechia

To describe the direct costs related to warfarin/apixaban treatment

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of non-valvular atrial fibrillation (NVAF);
* New initiation of anticoagulation therapy (apixaban or warfarin) due to the ischemic event (stroke/TIA) meaning patients previously not anticoagulated due to diagnosis of NVAF;
* Indication to anticoagulation therapy as a secondary stroke prevention within 7 to 30 days after the stroke/TIA event;
* Apixaban arm: genetically determined higher sensitivity to warfarin;
* Patients whose status allowed oral treatment with apixaban/warfarin;
* Age ≥ 18;
* Access to patient´s records of the first 6 months of the warfarin/apixaban treatment.

Exclusion Criteria:

* Diagnosis of valvular disease;
* Treatment with other anticoagulants in previous 6 months due to other the NVAF indication;
* Treatment or prophylaxis of deep vein thrombosis or pulmonary embolism;
* Contraindications according SmPC of Eliquis

Locations (1)

Prague, Czechia